Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers

Gynecologic Oncology

Volumn 115, Issue 1, 2009, Pages 135-137

  Vicus, Danielle ^a,b   Rosen, Barry ^a   Lubinski, Jan ^c   Domchek, Susan ^d   Kauff, Noah D ^e   Lynch, Henry T ^f   Isaacs, Claudine ^g   Tung, Nadine ^h   Sun, Ping ^b   Narod, Steven A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

BRCA1 mutation; Ovarian cancer; Tamoxifen

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENE MUTATION; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; ORAL CONTRACEPTION; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TAMOXIFEN;

EID: 69249217782     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.012     Document Type: Article

References (24)

1. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72 (2003) 1117-1130
2. Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Fan I., et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 98 (2006) 1694-1706
3. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
4. Metcalfe K.A., Lynch H.T., Ghadirian P., Tung N., Olivotto I.A., Foulkes W.D., et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol. Oncol. 96 (2005) 222-226
5. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., and Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86 (1994) 527-537
6. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90 (1998) 1371-1388
7. Beiner M.E., Finch A., Rosen B., Lubinski J., Moller P., Ghadirian P., et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol. Oncol. 104 (2007) 7-10
8. Lacey Jr. J.V., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 (2002) 334-341
9. Beral V., Bull D., Green J., and Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369 (2007) 1703-1710
10. Meyer U.A., and Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 269-296
11. Gronwald J., Tung N., Foulkes W.D., Offit K., Gershoni R., Daly M., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int. J. Cancer 118 (2006) 2281-2284
12. Metcalfe K., Lynch H.T., Ghadirian P., Tung N., Olivotto I., Warner E., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 22 (2004) 2328-2335
13. Clinton G.M., Rougeot C., Derancourt J., Roger P., Defrenne A., Godyna S., et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 316-320
14. Rao B.R., and Slotman B.J. Endocrine factors in common epithelial ovarian cancer. Endocr. Rev. 12 (1991) 14-26
15. Baldwin W.S., Curtis S.W., Cauthen C.A., Risinger J.I., Korach K.S., and Barrett J.C. BG-1 ovarian cell line: an alternative model for examining estrogen-dependent growth in vitro. In Vitro Cell. Dev. Biol. Anim. 34 (1998) 649-654
16. Hatch K.D., Beecham J.B., Blessing J.A., and Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 (1991) 269-271
17. Weiner S.A., Alberts D.S., Surwit E.A., Davis J., and Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 27 (1987) 208-213
18. Markman M., Iseminger K.A., Hatch K.D., Creasman W.T., Barnes W., and Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol. Oncol. 62 (1996) 4-6
19. Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med. Oncol. 24 (2007) 39-43
20. Markman M., Webster K., Zanotti K., Rohl J., and Belinson J. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol. Oncol. 93 (2004) 390-393
21. Cohen I., Beyth Y., Tepper R., Shapira J., Zalel Y., Figer A., et al. Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol. Oncol. 60 (1996) 54-58
22. Cook L.S., Weiss N.S., Schwartz S.M., White E., McKnight B., Moore D.E., and Daling J.R. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J. Natl. Cancer Inst. 87 (1995) 1359-1364
23. McGonigle K.F., Vasilev S.A., Odom-Maryon T., and Simpson J.F. Ovarian histopathology in breast cancer patients receiving tamoxifen. Gynecol. Oncol. 73 (1999) 402-406
24. Metcalfe K.A., Snyder C., Seidel J., Hanna D., Lynch H.T., and Narod S. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam. Cancer 4 (2005) 97-103